- Acquired by Olympus Corporation, Feb 2021
- Raised $20M funding round, Nov 2018
- Raised $8M funding round, Jul 2016
About
Medi-Tate develops new solutions for treating diseases of the urethra and prostate. Its solutions are designed to reduce associated symptoms and significantly improve patients' quality of life. The Medi-Tate device offers patients relief from the symptoms of benign prostate hyperplasia (BPH). The device is placed in the prostatic urethra for five days. During this time, it pushes obstructive tissue to the side, reshaping the prostate to create a long-term therapeutic effect. The device can be deployed in any clinical setting with standard rigid cystoscopy equipment. The deployment procedure is intuitive and does not require a postprocedural catheter. Once the device is deployed, the patient is free to return to normal activities immediately. Medi-Tate's iTind system for the treatment of BPH is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel. In April 2020, the company received an FDA De Novo classification for its iTind system.
Funding history · 3 rounds · $30.0M total
Q&A
- What is Medi-Tate's primary focus?
- Medi-Tate develops new solutions for treating diseases of the urethra and prostate, aiming to reduce symptoms and improve patients' quality of life.
- When was Medi-Tate acquired and by whom?
- Medi-Tate was acquired by Olympus Corporation in February 2021.
- What is the iTind system and its purpose?
- The iTind system is Medi-Tate's device for treating benign prostate hyperplasia (BPH). It is placed in the prostatic urethra for five days to reshape the prostate and provide a long-term therapeutic effect.
- In which markets is Medi-Tate's iTind system available?
- The iTind system is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel.
- When did Medi-Tate receive FDA De Novo classification for its iTind system?
- Medi-Tate received an FDA De Novo classification for its iTind system in April 2020.
- Who was a lead investor in Medi-Tate's November 2018 funding round?
- Olympus Corporation was an investor in Medi-Tate's November 2018 funding round.
- What was the total amount raised by Medi-Tate before its acquisition?
- Medi-Tate raised a total of $30,000,000 USD.
- Who are the co-founders of Medi-Tate?
- Ido Kilemnik is a co-founder and CEO of Medi-Tate.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | itind.com/ |
|---|---|
| linkedin.com/company/10291149 | |
| YouTube | youtube.com/channel/UCmYD_i77oo7BhHzeoVCQz_g |
| Wikidata | wikidata.org/wiki/Q50038698 |
Identifiers & details
| Founded | 2007-2 |
|---|---|
| Employees (exact) | 4 |
| Status reason | Acquired by Olympus Corporation on Feb, 2021 |
| Wikidata QID | Q50038698 |
Acquisitions & public offerings
Acquired by Olympus Corporation 2021-02
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | itind.com |
|---|
Wikidata
| QID | Q50038698 |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|